CD133 expression is reported to be indicative of a resistance phenotype [24], poor prognosis [25], and are believed to mediate cancer relapse after chemotherapy [26] and lower level of CD133 mRNA expression are documented to be associated with a longer relapse-free interval and overall survival (OS) in colon cancer [27]. The gene discussed is PROM1; the disease is malignant colon neoplasm.